Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
AssigneeImmune Design Corp.
InventorsThomas W. Dubensky, Jr., Scott H. Robbins
Life of this patent
Estimating the term…
Abstract
Compositions and methods are provided herein for improved dual immunization strategies that induce in a subject an immune response that includes a humoral immune response and cellular immune response, both CD4 and CD8 T lymphocyte immune responses, thereby providing a complete adaptive immune response to one or more antigens. The methods described are therefore useful for treating and/or preventing (i.e., reducing the likelihood or risk of occurrence) different diseases, disorders, and conditions such as cancers and infectious diseases for which induction of both a humoral immune response and cellular immune response is desired and beneficial.
Claims33
A method for priming and boosting a CD8 T cell immune response in a subject, the method comprising (a) administering to the subject at least one dose of a first immunogenic composition comprising (i) a lentiviral vector comprising a nucleotide sequence that encodes a first immunogen or an immunogenic fragment thereof, wherein the lentiviral vector is incorporated into a vector particle, wherein the vector particle comprises a lentiviral vector genome and an alpha virus envelope;
- and (b) subsequently administering to the subject at least one dose of a second immunogenic composition comprising (i) at least the first immunogen or an immunogenic fragment thereof and (ii) a TRL4 agonist, thereby priming and boosting a CD8 T cell immune response specific for the first immunogen, wherein the TRL4 agonist is a compound of the following structure:
- wherein A1 and A2 are independently selected from the group of hydrogen, phosphate, and phosphate salts and R1, R2, R3, R4, R5, and R6 are independently selected from the group of hydrocarbyl having 3 to 23 carbons, represented by C3-C23.
A method for priming and boosting a CD8 T cell immune response in a subject, the method comprising (a) administering to the subject at least one dose of a first immunogenic composition comprising (i) a lentiviral vector comprising a nucleotide sequence that encodes a first immunogen or an immunogenic fragment thereof, wherein the lentiviral vector is incorporated into a vector particle, wherein the vector particle comprises a lentiviral vector genome and an alpha virus envelope, and concurrently administering a second immunogenic composition comprising (i) at least the first immunogen or an immunogenic fragment thereof and (ii) a TRL4 agonist;
- and (b) subsequently administering the first and second immunogenic compositions of (a), thereby priming and boosting a CD8 T cell immune response specific for the first immunogen, wherein the TRL4 agonist is a compound of the following structure:
- wherein A1 and A2 are independently selected from the group of hydrogen, phosphate, and phosphate salts and R1, R2, R3, R4, R5, and R6 are independently selected from the group of hydrocarbyl having 3 to 23 carbons, represented by C3-C23.
Dependencies are inferred from the claim text.